Valeant Pharmaceuticals needs a 'fix it" third party to come in and stop the bleeding as the current management team is stuck in 'deer in headlights mode', and needs to resolve the overhang that is weighing down investor confidence on the street.
Valeant Pharmaceuticals (VRX) needs a 'fix it" third party to come in and stop the bleeding. Moreover, the current management team is stuck in 'deer in headlights mode', and needs to start taking proactive steps to resolve the overhang that is weighing down investor confidence on the street.
All of the content on EconMatters is provided without assurance or warranty of any kind. The opinions expressed here are personal views only, and no warranty of fitness for any particular use, merchantability or non-infringement is made. EconMatters is not intended to provide tax, legal, insurance or investment advice. Nothing should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. More here: http://www.econmatters.com/
Comments
Log in or sign up to join the conversation.